- Home
- KRP vs PHVS Comparison
KRP vs PHVS Comparison
Compare KRP & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRP
- PHVS
- Stock Information
- Founded
- KRP 2013
- PHVS 2015
- Country
- KRP United States
- PHVS Switzerland
- Employees
- KRP N/A
- PHVS N/A
- Industry
- KRP Oil & Gas Production
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- KRP Energy
- PHVS Health Care
- Exchange
- KRP Nasdaq
- PHVS Nasdaq
- Market Cap
- KRP 1.1B
- PHVS 980.9M
- IPO Year
- KRP 2017
- PHVS 2021
- Fundamental
- Price
- KRP $14.23
- PHVS $23.80
- Analyst Decision
- KRP Hold
- PHVS Buy
- Analyst Count
- KRP 5
- PHVS 6
- Target Price
- KRP $17.40
- PHVS $37.17
- AVG Volume (30 Days)
- KRP 531.5K
- PHVS 53.1K
- Earning Date
- KRP 08-07-2025
- PHVS 08-13-2025
- Dividend Yield
- KRP 12.10%
- PHVS N/A
- EPS Growth
- KRP N/A
- PHVS N/A
- EPS
- KRP 0.07
- PHVS N/A
- Revenue
- KRP $312,876,555.00
- PHVS N/A
- Revenue This Year
- KRP $10.45
- PHVS N/A
- Revenue Next Year
- KRP $3.27
- PHVS N/A
- P/E Ratio
- KRP $195.85
- PHVS N/A
- Revenue Growth
- KRP 3.03
- PHVS N/A
- 52 Week Low
- KRP $10.98
- PHVS $11.51
- 52 Week High
- KRP $17.07
- PHVS $26.33
- Technical
- Relative Strength Index (RSI)
- KRP 58.16
- PHVS 71.82
- Support Level
- KRP $13.93
- PHVS $17.63
- Resistance Level
- KRP $14.29
- PHVS $19.00
- Average True Range (ATR)
- KRP 0.25
- PHVS 1.59
- MACD
- KRP -0.03
- PHVS 0.67
- Stochastic Oscillator
- KRP 89.47
- PHVS 73.67
About KRP Kimbell Royalty Partners Common Units Representing Limited Partner Interests
Kimbell Royalty Partners LP owns and acquires mineral and royalty interests in oil and natural gas properties throughout the United States. The company's basins and producing regions include areas of interest in the Permian Basin, Mid-Continent, Terryville/Cotton Valley/Haynesville, Appalachian Basin, Eagle Ford, Bakken/Williston Basin, and DJ Basin/Rockies/Niobrara. Its revenues are derived from royalty payments received from operators based on the sale of oil, natural gas and NGL production, as well as the sale of NGLs that are extracted from natural gas during processing.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.